What are Medical Device De Novo Requests?

Updated October 26, 2024

A De Novo Request supports medical device regulation’s classification and approval process. Understanding the basics of a De Novo Request is essential for medical device manufacturers and innovators seeking market access for their new products. This article aims to explain the concept of De Novo Requests, highlight their significance in the FDA clearance process, provide insights into the submission process, evaluate possible outcomes, address challenges and considerations, and discuss the future of De Novo Requests in FDA regulation.

Key Takeaways

• De Novo applies to novel devices without a predicate.
• The FDA uses De Novo to classify new devices.
• It helps bring innovative low-to-moderate risk devices to market.
• Careful preparation is vital for successful submission.
• The De Novo pathway supports medical technology advancement.
• The FDA continues to refine the De Novo process efficiency.

Table of Contents

• Key Takeaways
• Understanding the Basics of De Novo Request
• The Importance of De Novo Request in Medical Device Classification
• The Process of Submitting a De Novo Request
• Evaluating the Outcome of a De Novo Request
• Challenges and Considerations in De Novo Request Process
• Future of De Novo Request in FDA Regulation

Why this matters

The De Novo Request pathway is pivotal for medical device innovation, enabling novel technologies to reach patients when no existing classification fits. Without it, many groundbreaking devices, particularly those with low to moderate risk profiles and no predicate, would face significant barriers to market entry. This mechanism ensures that such devices undergo appropriate scrutiny for safety and effectiveness without being arbitrarily classified as high-risk Class III devices, which demand more extensive and costly Premarket Approval (PMA) applications. The FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, underscores that cybersecurity is a fundamental aspect of device safety and effectiveness across all classifications, including those established via De Novo. Manufacturers pursuing a De Novo classification must therefore integrate cybersecurity considerations from the earliest design stages, aligning with recognized standards such as IEC 81001-5-1 for health IT safety and security, ISO 14971 for risk management, and AAMI TIR57 for medical device security risk management. Neglecting these areas can lead to significant delays or rejection, jeopardizing market access and patient safety. De Novo requests thus serve as a critical bridge, balancing innovation with stringent regulatory oversight, particularly in the evolving landscape of medical device cybersecurity.

Understanding the Basics of De Novo Request

Definition of De Novo Request

A De Novo Request, also known as a De Novo Classification or Evaluation of Automatic Class III Designation, is a submission to the U.S. Food and Drug Administration (FDA) to classify medical devices that do not have a legally marketed predicate device. In other words, it is a pathway for novel devices that do not fit within the existing classification framework.

When a manufacturer believes their new medical device does not have a suitable predicate device to reference for classification, they can opt for the De Novo Request process. This pathway allows the FDA to evaluate the device’s merits and determine the appropriate risk classification and regulatory requirements.

History and Evolution of De Novo Request

The De Novo Request process was introduced under the FDA Modernization Act of 1997 to improve the regulatory pathway for new medical devices, particularly those of low to moderate risk. Over the years, the process has evolved, with the FDA striving to streamline and expedite the evaluation of novel devices to facilitate innovation while maintaining patient safety.

As technology advances and new types of medical devices emerge, the De Novo Request pathway has become increasingly important in the FDA’s regulatory framework. It serves as a critical mechanism for ensuring timely market access for innovative medical technologies that do not have a predicate for comparison. The De Novo process supports building innovation and improving patient care by providing a clear pathway for evaluating and classifying such devices.

The Importance of De Novo Request in Medical Device Classification

Role of De Novo Request in FDA Clearance Process

The De Novo Request pathway supports the FDA clearance process by providing a mechanism for the initial classification of new and innovative devices. It allows manufacturers to seek FDA authorization and establish a classification for their devices. It is a foundation for subsequent regulatory activities, such as premarket submissions, quality control, and post-market surveillance.

The De Novo Request pathway offers a streamlined approach for devices that do not fit within existing classification categories or lack a predicate device. This flexibility is crucial in addressing the evolving landscape of medical technology, where traditional classification pathways may not adequately capture the unique features of novel devices. By classifying such devices, the De Novo Request pathway promotes regulatory clarity and expedites market access for innovative technologies.

Impact on Medical Device Innovation

The availability of the De Novo Request pathway has significantly impacted medical device innovation. Offering a pathway for devices without a predicate encourages manufacturers to develop and introduce novel technologies, building patient care and treatment advancements.

In addition to building innovation, the De Novo Request pathway also promotes competition and market diversity within the medical device industry. By enabling new entrants to bring unique products to market, it prevents monopolies and stimulates a competitive environment that ultimately benefits healthcare providers and patients. This competitive landscape encourages continuous improvement and drives companies to strive for excellence in product development and patient outcomes.

The Process of Submitting a De Novo Request

Preparing for a De Novo Submission

Submitting a successful De Novo Request requires careful preparation and a thorough understanding of the FDA’s requirements. Manufacturers should conduct research on their device, identifying its unique features, intended use, and potential risks. Gathering clinical data, conducting necessary testing, and ensuring compliance with relevant regulations are essential steps in the preparation process.

Manufacturers must establish a clear timeline for the submission process, taking into account internal review procedures and potential revisions based on FDA feedback. Engaging with regulatory consultants or experts in the field can provide valuable insights and guidance throughout the preparation phase, ensuring that the submission meets all necessary criteria for review.

Components of a De Novo Request

A well-constructed De Novo Request includes several key components highlighting the device’s safety, effectiveness, and patient benefits. These components typically include a device description, intended use and indications for use, labeling, risk analysis, clinical data, bench testing results, and a summary of any adverse events observed during studies or trials. Providing a and well-structured submission is crucial to enhance the chances of a favorable outcome.

Manufacturers should pay close attention to the formatting and organization of the submission, ensuring that all required sections are clearly labeled and easy to navigate. Providing detailed references and supporting documentation can strengthen the validity of the submission and help reviewers assess the device’s performance more effectively. Manufacturers can increase the likelihood of a successful De Novo Request approval by demonstrating a thorough understanding of the device and its potential impact on patient care.

Evaluating the Outcome of a De Novo Request

Possible Outcomes and Their Implications

Following the evaluation of a De Novo Request, the FDA can issue one of three outcomes: granting the request and establishing a new device classification, refusing the request, or requesting additional information to make an informed decision. The outcome has significant implications for the manufacturer and the market entry of the device. Positive outcomes can open doors to market access, reimbursement opportunities, and potential partnerships, while negative outcomes may require additional steps or modifications to address regulatory concerns.

When the FDA grants a De Novo Request, the agency has determined the device to be low to moderate risk and eligible for marketing authorization. This decision validates the manufacturer’s innovation and efforts and paves the way for commercialization in the healthcare landscape. Manufacturers can use this positive outcome to differentiate their products in a competitive market, attract investors, and establish credibility among healthcare providers and patients.

Understanding FDA’s Decision Criteria

See also: FDA Penetration Testing Requirements for Medical Devices, Letter to File vs New 510(k) for Cybersecurity Changes, and Special vs Traditional 510(k) for Cybersecurity Changes.

The FDA evaluates De Novo Requests based on specific criteria, including the device’s intended use, technological characteristics, safety and effectiveness, patient risks and benefits, and comparison to predicate devices. Manufacturers must address these criteria thoroughly, providing evidence and scientific reasoning to support the request. Familiarizing oneself with the FDA’s decision-making process can guide manufacturers in constructing a compelling De Novo Request.

Manufacturers should consider engaging with regulatory consultants or experts who have experience navigating the FDA’s review processes. These professionals can offer valuable insights, help identify potential pitfalls, and assist in developing a strategy to increase the likelihood of a favorable outcome. Manufacturers can enhance their chances of success in the De Novo Request process by proactively addressing the FDA’s decision criteria and seeking expert guidance.

Challenges and Considerations in De Novo Request Process

When navigating the De Novo request process, manufacturers encounter various challenges that require careful consideration and strategic planning. In addition to the common pitfalls mentioned, it is essential to anticipate potential regulatory hurdles and market complexities that could impact the device’s clearance. Manufacturers must also stay informed about the evolving regulatory landscape and be prepared to adapt their submission strategy accordingly.

Furthermore, understanding the competitive landscape and market dynamics is crucial for positioning the device effectively within the industry. Conducting thorough market research and identifying unmet clinical needs can help manufacturers tailor their De Novo request to highlight the device’s unique value proposition and differentiation from existing solutions.

Common Pitfalls in De Novo Submission

Manufacturers should know common pitfalls in the De Novo submission process to avoid unnecessary delays or rejections. Some common challenges include inadequate data supporting the device’s safety or effectiveness, lack of clarity in the intended use and indications, failure to distinguish the device from existing predicates, and incomplete or poorly organized submission materials.

Strategies for Successful De Novo Request

Manufacturers can employ various strategies to increase the likelihood of a successful De Novo Request. These may include involving regulatory experts early in the development process, conducting testing and clinical studies, engaging with the FDA through pre-submission meetings or consultations, addressing the FDA’s decision criteria clearly and concisely, and providing evidence to support the device’s safety and effectiveness claims.

Future of De Novo Request in FDA Regulation

Recent Changes and Their Impact

In recent years, the FDA has introduced changes to streamline the De Novo Request process and enhance efficiency. These changes aim to reduce the time required for evaluation, improve communication with manufacturers, and facilitate the development of novel medical devices. Understanding these changes and adapting to the evolving regulatory landscape is essential for manufacturers navigating the De Novo Request pathway.

One significant change implemented is the introduction of the Pre-Submission Program. This program allows manufacturers to engage with the FDA early in the development process, providing an opportunity for feedback and guidance. Manufacturers can address potential issues by seeking input from the FDA before submitting a De Novo Request and ensuring that their submission meets the requirements. This proactive approach saves time and increases the chances of a successful approval.

Predicted Trends in De Novo Request Usage

The use of De Novo Requests is expected to continue increasing as innovation in medical devices advances. With the growing complexity and diversity of technologies, the De Novo pathway provides a flexible framework for introducing novel devices, ensuring patient access to advanced healthcare solutions. Manufacturers should stay informed about emerging trends and developments in De Novo Requests to remain competitive in the dynamic medical device market.

One emerging trend is using artificial intelligence (AI) in medical devices. AI-powered devices have the potential to revolutionize healthcare by improving diagnostic accuracy, enabling personalized treatments, and enhancing patient monitoring. As these innovative AI devices enter the market, manufacturers must navigate the De Novo Request process to ensure compliance with FDA regulations. Understanding how AI fits within the De Novo framework and addressing any unique challenges associated with these devices will be crucial for manufacturers seeking approval.

Conclusion

A De Novo Request with the FDA is an essential mechanism that enables the classification and approval of novel medical devices that do not have a predicate device. Understanding the fundamentals of a De Novo Request, recognizing its significance in the FDA clearance process, and navigating the submission process effectively is vital for manufacturers and innovators in the medical device industry. By embracing the challenges, employing successful strategies, and staying abreast of the evolving regulatory landscape, manufacturers can use the De Novo pathway to promote medical device innovation and improve patient care.

As the medical device industry continues to innovate and navigate the complexities of FDA regulations, the importance of cybersecurity measures cannot be overstated. Blue Goat Cyber, a Veteran-Owned business, specializes in medical device cybersecurity, ensuring that your products meet all necessary compliance standards, including HIPAA and FDA regulations. Our expertise in penetration testing and commitment to securing your business makes us an ideal partner in your journey to market. Contact us today for cybersecurity help and safeguard your medical devices against potential threats.

How Blue Goat approaches this

Blue Goat Cyber assists medical device manufacturers in preparing strong De Novo submissions by focusing on verifiable cybersecurity evidence. Our process begins with an in-depth analysis of the proposed device's cybersecurity architecture and intended use environment. We help identify potential vulnerabilities, assess associated risks, and develop appropriate mitigation strategies in line with the FDA's expectations for novel devices. Our team, comprised of certified professionals like CISSP and OSCP holders, including ex-military red team personnel, specializes in developing rigorous documentation for cybersecurity controls and testing. We guide manufacturers through threat modeling, risk management, and control implementation, producing the necessary materials for a successful De Novo classification. Our goal is to streamline the regulatory process. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at: /services/fda-premarket-cybersecurity-services.

FAQ

What is a De Novo Request?

A De Novo Request is a pathway for the FDA to classify novel medical devices that have no legally marketed predicate device into Class I or Class II, based on their risk level. This process allows these devices to enter the market.

When should a manufacturer consider a De Novo Request?

Manufacturers should consider a De Novo Request when their medical device is novel and does not fit within an existing classification, meaning there is no predicate device for a 510(k) submission, or if a 510(k) has been deemed Not Substantially Equivalent (NSE).

How does the De Novo process impact medical device innovation?

The De Novo process significantly builds medical device innovation by providing a clear regulatory pathway for novel devices, encouraging manufacturers to develop new technologies, and Ensure patient access to advanced healthcare solutions.

What information is needed for a De Novo submission?

A De Novo submission requires a device description, intended use, indications for use, labeling, detailed risk analysis, clinical data, and bench testing results, all supporting the device's safety and effectiveness.

What are the possible outcomes of a De Novo Request?

The FDA can grant the request, establishing a new device classification; refuse the request; or ask for additional information. A granted request opens opportunities for market access and further development.

Does the FDA premarket cybersecurity guidance apply to De Novo devices?

Yes, all medical devices, including those cleared through the De Novo pathway, must comply with the FDA's February 3, 2026 final guidance on premarket cybersecurity. Cybersecurity is a critical aspect of device safety and effectiveness.

Related: Medical Device Cybersecurity: A Complete Lifecycle Guide

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.